MammoTest Brochure

Transcription

MammoTest Brochure
+120º
28 cm (11in)
72cm (28.3in)
88cm (34.6in)
94cm (37in)
accurate.easy.comfortable.
stereotactic biopsy table
Mammotome MammoTest™ Features
• ergonomic table with large central breast aperture
(measuring 11 inches)
• fully digital detector uses CCD of 1024 x 1024 pixels
• detector resolution: 10 lp/mm
• spot field of view: 50 x 50 mm
-120º
• Target on Scout for exact needle positioning
• true 360 degree access without moving the patient
• lateral arm for close needle access to lesion
• unique table design minimizes patient repositioning
183cm (72in)
• PACS and DICOM - compatible for high connectivity and
198cm (78 in)
increased workflow efficiency
• optional mobility kit: includes wheels under the table that create
mobility and frees up space in the room for other procedures
+ W EB: www.mammotome.com
MDM 14-0021 Rev 05/14
+ EMA IL: [email protected]
+ F AX:
©2014 Devicor® Medical Products, Inc.
All rights reserved. For complete product
details, see Instructions for Use.
1-888-260-6362
+ PHONE: 1-877-9-A-MAMMO
Please contact your Mammotome representative.
for more information
accurate.easy.comfortable.
Bringing more to the table.
superior per formance
Mammotome MammoTest™ for a
precise and efficient diagnosis.
We know how challenging a breast biopsy can be for
both you and your patient. This is why we have integrated
Mammotome MammoTest™ — a fully digital prone
biopsy table — into our portfolio of comprehensive
breast care solutions. Mammotome MammoTest™ is
designed with maximum access and targeting, as well
as utmost patient and user comfort.
accurate.
easy.
comfortable.
The Mammotome MammoTest™ table
brings optimized access through:
An optimized and minimized number of
procedural steps make the procedure
intuitive, efficient and patient friendly. A
wide range of gantry movement avoids
patient repositioning. With Mammotome
MammoTest™, the patient always rests
in a more comfortable prone position.
The Mammotome MammoTest™ ensures
that the whole procedure is kept out of
your patient’s view, while allowing for
easy eye contact and conversation.
Further ergonomic features reduce
shoulder and back stress. All this helps
to minimize patient stress and provides:
• angled targeting via polar coordinates
• all-angles 360 degree access
• Target on Scout option
• lateral arm option
• arm-through-hole technique
Bringing more to the table.
Together, Mammotome MammoTest™, Mammotome revolve® and Mammotome CoreVision®
provide an integrated approach to redefining procedural efficiency without compromising tissue
quality – from positioning to diagnosis. Mammotome revolve® offers the latest advancements in
VAB technology, designed for accuracy and unparalleled efficiency while staying true to your core
purpose – acquiring the best quality tissue during your patient’s biopsy. Mammotome CoreVision®
verifies the presence of micro-calcifications in core biopsies, rapidly confirming a successful biopsy
procedure right in the stereotactic suite.
• utmost patient comfort
• efficiency and comfort for the user

Similar documents

accurate.easy.comfortable.

accurate.easy.comfortable. Together, Mammotome MammoTest™, Mammotome revolve® and Mammotome CoreVision® provide an integrated approach to redefining procedural efficiency without compromising tissue quality – from positionin...

More information

experienced. focused. evolving. just like you.

experienced. focused. evolving. just like you. + Phone: Contact your Mammotome Customer Service Representative at 1-877-9-A-MAMMO between the hours of 8:30am and 6:30pm est. Shipping details and an order confirmation number will be provided to...

More information

Liquid Biopsy Market Revenue, Opportunity, Forecast and Value Chain 2016-2026

Liquid Biopsy Market Revenue, Opportunity, Forecast and Value Chain 2016-2026 Liquid biopsy is minimally invasive diagnostic procedure alternative to surgical biopsies. Liquid biopsy helps in collection of a wide range of information about a cancer/tumor through a simple blood sample. The procedure can help in exact detection of mutations in epidermal growth factor receptors in cancers such Non-Hodgkin’s Lymphoma (NSCLC). Furthermore, identification of traces of the cancer’s DNA in the blood could help in administration of precision treatments that could increase the probability of treatment effectiveness. Liquid biopsies are also helpful in residual cancer detection. This minimally invasive method can be performed with 5 milliliters of blood which would detect present state of metastases in various tumors. The liquid biopsy process is witnessing increasing adoption as it is easier to tolerate and much quicker than a surgical biopsy. The method is expected to emerge as a game changer in the field of oncology in the forthcoming years.

More information